Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 12/20 | 0.52 |
| ▸ | CTSD | P07339 | 4/20 | 0.52 |
| ▸ | TASP1 | Q9H6P5 | 1/20 | 0.50 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.49 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.49 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.49 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.49 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.49 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.49 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.49 |
| ▸ | ENPEP | Q07075 | 5/20 | 0.48 |
| ▸ | KISS1R | Q969F8 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29630649 | 0.90 | ENPEP (0.54) | BACE1CTSDENPEP | |
| SCHEMBL29590410 | 0.90 | GRIN2D (0.52) | BACE1CTSDTASP1GRIN2DGRIN3B | |
| SCHEMBL31480011 | 0.88 | ENPEP (0.50) | BACE1CTSDENPEP | |
| SCHEMBL31287158 | 0.88 | ENPEP (0.54) | BACE1TASP1ENPEP | |
| SCHEMBL30355008 | 0.87 | ENPEP (0.58) | BACE1TASP1ENPEP | |
| SCHEMBL30220501 | 0.87 | ENPEP (0.57) | BACE1TASP1ENPEP | |
| SCHEMBL29799784 | 0.87 | ENPEP (0.51) | BACE1CTSDTASP1ENPEP | |
| SCHEMBL10621016 | 0.87 | TASP1 (0.59) | BACE1CTSDTASP1GRIN2DGRIN3B | |
| SCHEMBL29630613 | 0.87 | BACE1 (0.49) | BACE1CTSD | |
| SCHEMBL30512767 | 0.87 | BACE1 (0.53) | BACE1CTSDTASP1GRIN2DGRIN3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12618102-B2 | Biochemical reaction methods and reagents comprising intrinsically disordered regions | Biocrucible Limited (GB) | 2026-05-05 | — | — | US | disclosed |
| US-20220112547-A1 | BIOCHEMICAL REACTION METHODS AND REAGENTS COMPRISING INTRINSICALLY DISORDERED REGIONS | Biocrucible Limited (GB) | 2022-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12618102-B2 | Biochemical reaction methods and reagents comprising intrinsically disordered regions | POLM, POLR1A, POLR1E | BACE1 530/4885CTSD 3399/4885TASP1 669/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.